{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:48:14Z","timestamp":1781711294807,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>In the <jats:styled-content style=\"fixed-case\">FIRST<\/jats:styled-content> trial (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\u2010020), lenalidomide plus low\u2010dose dexamethasone (Rd) reduced the risk of disease progression or death compared with combination melphalan\u2013prednisone\u2013thalidomide. As the <jats:styled-content style=\"fixed-case\">FIRST<\/jats:styled-content> trial did not include any Japanese patients, the efficacy and safety of continuous treatment with Rd was evaluated in 26 Japanese patients with newly diagnosed multiple myeloma (<jats:styled-content style=\"fixed-case\">NDMM<\/jats:styled-content>) in a single\u2010arm, multicenter, open\u2010label phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>\u2010025). Patients received lenalidomide on days\u00a01\u201321 of each 28\u2010day cycle, with a starting dose of 25\u00a0mg\/day (dose adjusted for renal impairment), and 40\u00a0mg\/day dexamethasone (dose adjusted for age) on days 1, 8, 15 and 22 of each 28\u2010day cycle until disease progression or discontinuation for any reason. In the efficacy evaluable population, overall response rate was 87.5%, including 29.2% of patients who achieved a complete response\/very good partial response. Median durations of response, progression\u2010free survival and overall survival have not been reached. The most common grade\u00a03\u20134 adverse events were neutropenia (23%) and anemia (19%). The efficacy and safety of Rd were consistent with data from larger studies, including the <jats:styled-content style=\"fixed-case\">FIRST<\/jats:styled-content> trial, thereby supporting the use of Rd continuous in Japanese patients with <jats:styled-content style=\"fixed-case\">NDMM<\/jats:styled-content> who are ineligible for stem cell transplantation.<\/jats:p>","DOI":"10.1111\/cas.12916","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T03:16:41Z","timestamp":1456456601000},"page":"653-658","source":"Crossref","is-referenced-by-count":12,"title":["Lenalidomide and low\u2010dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase <scp>II<\/scp> study"],"prefix":"10.1111","volume":"107","author":[{"given":"Kenshi","family":"Suzuki","sequence":"first","affiliation":[{"name":"Japanese Red Cross Medical Center Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shinagawa","sequence":"additional","affiliation":[{"name":"Hitachi General Hospital Hitachi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[{"name":"University Hospital, Kyoto Prefectural University of Medicine Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Hematology Kansai Electric Power Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy Yamagata University Faculty of Medicine Yamagata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[{"name":"Kameda General Hospital Kamogawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Tokai University Hospital Isehara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine Keio University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kagoshima Medical Center Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nishigunma National Hospital Shibukawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Nagoya City University Hospital Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[{"name":"The Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Kinki University Hospital Osakasayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center Sunto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[{"name":"National Hospital Organization Disaster Medical Center Tachikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Ogaki","sequence":"additional","affiliation":[{"name":"Celgene K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Midorikawa","sequence":"additional","affiliation":[{"name":"Celgene K.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Houck","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Ervin\u2010Haynes","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Chou","sequence":"additional","affiliation":[{"name":"Niigata Cancer Center Hospital Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"issue":"10","key":"e_1_2_7_2_1","first-page":"1850","article-title":"Guideline for multiple myeloma","volume":"54","author":"Japanese Society of Hematology","year":"2013","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6180"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341669"},{"key":"e_1_2_7_8_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines: Multiple myeloma. Version 2.2015. [Cited 9 September 2015.] Available from URL:http:\/\/www.nccn.org."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.03.005"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12982"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117457"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"Abstract 4240","DOI":"10.1182\/blood.V126.23.4240.4240","article-title":"Continuous treatment with lenalidomide and low\u2010dose dexamethasone in transplant\u2010ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the First Trial [abstract]","volume":"126","author":"Lu J","year":"2015","journal-title":"Blood"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0624-7"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1966-z"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_7_23_1","unstructured":"Revlimid\u00aeprescribing information. [Cited 27 December 2015.] US available from URL:http:\/\/www.revlimid.com\/wp-content\/uploads\/full-prescribing-information.pdf. Japan. [Cited 27 December 2015] available from URL:http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/380809_4291024M1024_1_21. (Article in Japanese.)"},{"issue":"23","key":"e_1_2_7_24_1","first-page":"I4","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White RH","year":"2003","journal-title":"Circulation"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432203"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"Abstract 687","DOI":"10.1182\/blood.V122.21.687.687","article-title":"A simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients [abstract]","volume":"122","author":"Larocca A","year":"2013","journal-title":"Blood"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12916","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:37:59Z","timestamp":1696354679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/cas.12916"],"URL":"https:\/\/doi.org\/10.1111\/cas.12916","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}